Corporate ActionApr 27, 2026, 06:08 AM
SPTX Files S-1/A for IPO of 11.8M Shares at $16-$18
AI Summary
Seaport Therapeutics, Inc. filed an S-1/A for its initial public offering, proposing to offer 11,800,000 shares of common stock at an estimated price range of $16.00 to $18.00 per share. The company, a clinical-stage therapeutics firm, also provided updates on its pipeline, including positive Phase 1 data for GlyphAgo, showing a 6.8-fold increase in bioavailability, and ongoing Phase 2b trials for GlyphAllo with topline data expected in H1 2027. SPTX plans to list on the Nasdaq Global Market under 'SPTX'.
Key Highlights
- Initial public offering of 11,800,000 common shares.
- Estimated IPO price range between $16.00 and $18.00 per share.
- Underwriters have option to purchase additional 1,770,000 shares.
- General Atlantic affiliates indicated interest to purchase up to $50 million in shares.
- GlyphAgo Phase 1 showed 6.8-fold increase in agomelatine bioavailability.
- GlyphAgo Phase 1 showed 9.6 to 14.5-fold increase in dose-normalized exposure.
- GlyphAllo Phase 2b BUOY-1 trial for MDD expects topline data in H1 2027.
- Company raised $325 million in net proceeds from investors since inception.